Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptIMMize-2 risankizumab extension study in pediatric plaque psoriasis
2022-500408-22-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc. Primary endpoint: Number of participants with adverse events. Planned start Sep 2022; status: authorised.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-500408-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500408-22-00.